New hope for kids with tough neuroblastoma: drug combo trial opens
NCT ID NCT07437963
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times
Summary
This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlling the cancer. About 76 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GANGLIONEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
- Supercharged immune cells take aim at childhood cancers
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
- Engineered immune cells take aim at childhood cancer